Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to post sales of $26.22 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $21.15 million and the highest is $39.80 million. Nektar Therapeutics reported sales of $95.47 million during the same quarter last year, which would suggest a negative year over year growth rate of 72.5%. The business is scheduled to issue its next earnings report on Thursday, March 7th.
According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $1.18 billion for the current year, with estimates ranging from $1.17 billion to $1.20 billion. For the next year, analysts anticipate that the business will report sales of $457.12 million, with estimates ranging from $135.00 million to $1.18 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.07. The company had revenue of $27.80 million for the quarter, compared to analyst estimates of $26.08 million. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. Nektar Therapeutics’s revenue for the quarter was down 81.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.37 EPS.
Shares of Nektar Therapeutics stock traded down $2.64 during trading on Friday, hitting $35.31. 4,322,822 shares of the stock were exchanged, compared to its average volume of 3,121,603. The firm has a market capitalization of $6.22 billion, a PE ratio of -64.20 and a beta of 2.91. Nektar Therapeutics has a 1-year low of $30.30 and a 1-year high of $111.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 19.67 and a quick ratio of 19.55.
In other Nektar Therapeutics news, Director Dennis L. Winger sold 34,250 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares of the company’s stock, valued at approximately $3,628,425. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dennis L. Winger sold 30,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the sale, the director now directly owns 57,750 shares of the company’s stock, valued at approximately $3,462,690. The disclosure for this sale can be found here. Insiders have sold a total of 96,000 shares of company stock valued at $5,825,680 in the last ninety days. 4.31% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of NKTR. FMR LLC boosted its holdings in Nektar Therapeutics by 6.7% in the 2nd quarter. FMR LLC now owns 25,705,902 shares of the biopharmaceutical company’s stock valued at $1,255,220,000 after purchasing an additional 1,608,834 shares during the period. First Trust Advisors LP boosted its holdings in Nektar Therapeutics by 176.2% in the 3rd quarter. First Trust Advisors LP now owns 2,068,900 shares of the biopharmaceutical company’s stock valued at $126,120,000 after purchasing an additional 1,319,776 shares during the period. OppenheimerFunds Inc. boosted its holdings in Nektar Therapeutics by 7.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 11,560,779 shares of the biopharmaceutical company’s stock valued at $564,512,000 after purchasing an additional 845,257 shares during the period. Advisors Asset Management Inc. bought a new stake in Nektar Therapeutics in the 2nd quarter valued at about $373,000. Finally, BB Biotech AG bought a new stake in Nektar Therapeutics in the 2nd quarter valued at about $25,636,000. 92.72% of the stock is owned by hedge funds and other institutional investors.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Read More: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.